Skip to main navigation Skip to search Skip to main content

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study

  • Ursula Schmidt-Erfurth*
  • , Bora Eldem
  • , Robyn Guymer
  • , Jean Franois Korobelnik
  • , Reinier O. Schlingemann
  • , Ruth Axer-Siegel
  • , Peter Wiedemann
  • , Christian Simader
  • , Margarita Gekkieva
  • , Andreas Weichselberger
  • *Corresponding author for this work
  • University of Vienna
  • Hacettepe University
  • University of Melbourne
  • Groupe hospitalier Pellegrin
  • Academic Medical Centre
  • Rabin Medical Center Israel
  • Leipzig University
  • Medical University of Vienna
  • Novartis

Research output: Contribution to journalArticlepeer-review

375 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science